Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 5-18 , January 2010

What Does the Generalist Need to Know About HIV Infection?

  • Joel E. Gallant

      Affiliations

    • Corresponding Author InformationAddress correspondence to Joel E. Gallant, MD, MPH, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 443, Baltimore, MD 21205.

References 

  1. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701–706
  2. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:106–114
  3. Landon BE, Wilson IB, McInnes K, et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch Intern Med. 2005;165:1133–1139
  4. Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS. 1998;12:417–424
  5. Kitahata MM, Van Rompaey SE, Dillingham PW, et al. Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. J Gen Intern Med. 2003;18:95–103
  6. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther. 2003;8:471–478
  7. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep. 2006;55:1–14
  8. Centers for Disease Control and Prevention. Late versus early testing of HIV–16 sites, United States 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52:581–586
  9. Egger M: Outcomes of ART in resource limited and industrialized countries [Abstract 62]. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles.
  10. Bartlett JG, Branson BM, Fenton K, et al. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300:945–951
  11. Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. Am J Med. 2005;118:292–300
  12. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–585
  13. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States—An analysis of cost-effectiveness. N Engl J Med. 2005;352:586–595
  14. Centers for DiseaseControl and Prevention web site. Available at: http://www.cdc.gov/hiv/. Accessed May 24, 2009
  15. Chou R, Huffman LH, Fu R, et al. Screening for HIV: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:55–73
  16. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651–681
  17. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 24, 2009
  18. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection; 2008 recommendations of the International AIDS Society USA panel. JAMA. 2008;300:555–570
  19. CDC, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 2009;58:1–207
  20. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohorts. Lancet. 2009;373:1352–1363
  21. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826
  22. Reynolds S, Makumbi F, Kagaayi J, et al: ART Reduced the Rate of Sexual Transmission of HIV among HIV-discordant Couples in Rural Rakai, Uganda [Abstract 52a]. 16th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2009, Montreal.
  23. Sullivan P, Kayitenkore K, Chomba E, et al: Reduction of HIV transmission risk and high risk sex while prescribed ART: Results from discordant couples in Rwanda and Zambia [Abstract 52bLB]. 16th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2009, Montreal.
  24. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  25. El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296
  26. Weltz T, Childs K, Ibrahim F, et al: Efavirenz use is associated with severe vitamin D deficiency in a large, ethnically diverse urban HIV cohort [Abstract TUPEB186]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19–22, 2009. Cape Town, South Africa

 In the last 12 months, Dr Gallant has served on advisory boards, data safety monitoring boards, or as a consultant for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Japan Tobacco, Koronis, Merck, Monogram Biosciences, Pfizer, RAPID Pharmaceuticals, Tibotec, and VIRxSYS. Johns Hopkins University has received research funding from Roche for clinical research being conducted by Dr. Gallant. Dr. Gallant does not have stock holdings in pharmaceutical companies and is not a member of any speakers' bureaus.

PII: S1548-5595(09)00158-X

doi: 10.1053/j.ackd.2009.08.003

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 5-18 , January 2010

Article Tools